Friday's big stock stories: What’s likely to move the market in the next trading session

Regulatory pressure on obesity drug pricing, signaled by President Trump, led to after-hours declines for Novo Nordisk and Eli Lilly, while investor optimism for a "new era" in personalized medicine is driving biotech ETF gains. Concurrently, Ark Invest increased exposure to Chinese internet stocks like Alibaba and Baidu, which have seen substantial three-month rallies. The 10-year Treasury yield dropped below 4%, influencing bond markets, as the regional banking sector continues its multi-week decline ahead of key earnings reports, contrasting with gold's robust 29% two-month surge to new highs.

Analysis

President Trump's comments on obesity drug pricing immediately impacted major pharmaceutical stocks, with Novo Nordisk falling almost 4% and Eli Lilly nearly 5% after hours. This regulatory uncertainty adds significant downside risk to companies heavily reliant on these drug categories, evidenced by Novo Nordisk's over 50% year-on-year decline.

Conversely, the biotech sector shows signs of a breakout, with ETFs like IBB and XBI gaining 6.3% and 7.7% respectively in October, driven by optimism for personalized medicine. Simultaneously, Ark Invest's increased positions in Chinese internet giants Alibaba and Baidu highlight renewed institutional confidence, as both stocks have rallied over 40% in the last three months.

The 10-year Treasury yield dropping below 4% signals broader market shifts, while high-yield corporate bond ETFs offer yields up to 7.06%. In contrast, the regional banking sector remains under significant pressure, with the KRE ETF down for four consecutive weeks and 9% in the last month, ahead of critical earnings reports from major players.

Gold continues its strong upward trajectory, reaching new highs with a 29% gain over two months, marking its best weekly performance since March 2020. This robust performance is reflected in the VanEck Gold Miners ETF (GDX), which surged 11.7% in five days, indicating strong investor demand for safe-haven assets.

Key Decisions for Investors

• Investors should assess exposure to pharmaceutical companies with significant revenue from obesity drugs, given heightened regulatory pricing pressure.
• Consider increasing allocations to biotech ETFs, such as IBB or XBI, to capitalize on the personalized medicine theme and recent sector momentum.
• Monitor regional bank earnings closely for further indications of sector stability or continued weakness, particularly for KRE and individual names reporting.
• Evaluate gold and gold miner ETFs (GDX) for continued safe-haven appeal and momentum, while also considering high-yield corporate bond ETFs for attractive income opportunities following the 10-year yield drop.